Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGN-440 (Beloranib) in Obese Subjects With Type 2 Diabetes
NCT02324491Phase 2Terminated
- Sponsor
- Zafgen, Inc.
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of beloranib in obesity, type 2 diabetes mellitus (T2DM), sponsored by Zafgen, Inc.. Started Dec 2014; status: terminated.
02
Drugs
beloranib
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02324491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324491.